Janssen R&D announced the addition of three new clinical trials under the EXPLORER global cardiovascular research program for Xarelto (rivaroxaban) to be evaluated for thromboembolic disorders.
The researchers found that the risk of developing an intraocular hemorrhage was reduced with dabigatran or rivaroxaban at 365 days (hazard ratio, 0.75; 95% confidence interval, 0.58 to 0.97; P=0.03) but not at 90 days (hazard ratio, 0.73; 95% confidence interval, 0.22 to 2.63; P=0.13).
Because of various clinical situations, there may be a need for clinicians to transition patients from one anticoagulant therapy to another. In order to do this safely, the pharmacology profiles of both agents should be taken into consideration.
Janssen Pharmaceuticals announced that the FDA has approved Xarelto (rivaroxaban) tablets to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Janssen Research & Development announced that it has submitted a supplemental New Drug Application (sNDA) to the FDA seeking approval for the use of Xarelto (rivaroxaban) to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome (ACS).
